Adaptive COVID-19 Treatment Trial 3 (ACTT-3)

NCT04492475 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

969

Enrollment

NIH

Sponsor class

Conditions

COVID-19

Interventions

DRUG: Interferon beta-1a
OTHER: Placebo
DRUG: Remdesivir

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)